A comparative study of imipenem/cilastatin sodium bid vs qid in the treatment of infections associated with hematopoietic disorders

Yoshiro Sawae; Yoshiyuki Niho; Takashi Okamura; Masahiro Murakawa; Takanori Teshima; Tomoaki Fujisaki; Kei Ikeda; Mitsuo Kozuru; Naokuni Uike; Makoto Katsuno; Hiroyuki Takahira; Michi Hashimoto; Sayuri Yamashita; Kousuke Obama; Junji Nishimura; Syusuke Hisano; Eiji Morioka; Morioki Ishibashi; Tomi Akiyoshi; Junji Suzumiya; Hiroaki Nakajima; Toshiki Uchida; Tetsuya Yoshida; Fumitoshi Asahara; Kouko Sakai; Naohisa Takeichi; Hideki Ishikura; Atsushi Takita; Ryokichi Asayama; Tsunefumi Shibuya; Kazuo Yamasaki; Shuichi Taniguchi; Hisashi Gondoh; Shin Hayashi; Kouichi Akashi; Seiji Motomura; Toshiyuki Ishimaru; Yusei Yamamoto; Kimiaki Ikeda; Yujiroh Yamano; Hiromi Iwasaki; Masayuki Sano; Yoshiroh Ohta; Eijo Matsuishi; Shinichi Hiramatsu; Akihiro Masumoto; Hideaki Kishikawa; Shuichi Koarada

doi:10.11553/antibiotics1968b.47.1318

A comparative study of imipenem/cilastatin sodium bid vs qid in the treatment of infections associated with hematopoietic disorders

Yoshiro Sawae, Yoshiyuki Niho, Takashi Okamura, Masahiro Murakawa, Takanori Teshima, Tomoaki Fujisaki, Kei Ikeda, Mitsuo Kozuru, Naokuni Uike, Makoto Katsuno, Hiroyuki Takahira, Michi Hashimoto, Sayuri Yamashita, Kousuke Obama, Junji Nishimura, Syusuke Hisano, Eiji Morioka, Morioki Ishibashi, Tomi Akiyoshi, Junji SuzumiyaHiroaki Nakajima, Toshiki Uchida, Tetsuya Yoshida, Fumitoshi Asahara, Kouko Sakai, Naohisa Takeichi, Hideki Ishikura, Atsushi Takita, Ryokichi Asayama, Tsunefumi Shibuya, Kazuo Yamasaki, Shuichi Taniguchi, Hisashi Gondoh, Shin Hayashi, Kouichi Akashi, Seiji Motomura, Toshiyuki Ishimaru, Yusei Yamamoto, Kimiaki Ikeda, Yujiroh Yamano, Hiromi Iwasaki, Masayuki Sano, Yoshiroh Ohta, Eijo Matsuishi, Shinichi Hiramatsu, Akihiro Masumoto, Hideaki Kishikawa, Shuichi Koarada

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Using the envelope method, we allocated 125 patients with infections accompanied by hematopoietic disorders into two groups treated with imipenem/cilastatin sodium (IPM/CS) at a daily dose of 1 g/1 g b.i.d. (group BID) or 0.5 g/0.5 g q.i.d. (group QID), and obtained the following results. 1. in group BID, ANLL was observed in 25 patients; ALL in 6; and NHL in 12. in group QID, ANLL was observed in 27 patients; ALL in 7; and NHL in 13. 2. in group BID, efficacy rates were 54.5% (6/11) in sepsis, 63.0% (17/27) in fever of undetermined origin and 50.0% (4/8) in pneumonia, thus the overall efficacy was 61.8% (34/55). in group QID, efficacy rates were 66.7% (4/6) in sepsis, 76.0% (19/25) in fever of undetermined origin and 35.7% (5/14) in pneumonia, thus the over all was 61.1% (33/54). No significant difference in response rates were observed between the two groups. 3. Bacteriologically, 22 bacterial strains were isolated in group BID and 21 strains, in group QID. the eradication rates after treatment with IPM/CS was 100% in group BID and 66.7% in group QID. 4. Side effects were observed in 8 patients in group BID and 3 in group QID. Laboratory examination revealed abnormal values in 9 patients in group BID and 6 in group QID. However, all of the side effects desappeared after the suspension or discontinuation of IPM/CS. the efficacies of IPM/CS therapy for severe infections in patients with hematopoietic disease were similar between 1 g/1 g b.i.d. and 0.5 g/0.5 g q.i.d. groups.

Original language	English
Pages (from-to)	1318-1328
Number of pages	11
Journal	The Japanese Journal of Antibiotics
Volume	47
Issue number	10
DOIs	https://doi.org/10.11553/antibiotics1968b.47.1318
Publication status	Published - 1994
Externally published	Yes

All Science Journal Classification (ASJC) codes

Microbiology (medical)
Pharmacology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11553/antibiotics1968b.47.1318

Cite this

Sawae, Y., Niho, Y., Okamura, T., Murakawa, M., Teshima, T., Fujisaki, T., Ikeda, K., Kozuru, M., Uike, N., Katsuno, M., Takahira, H., Hashimoto, M., Yamashita, S., Obama, K., Nishimura, J., Hisano, S., Morioka, E., Ishibashi, M., Akiyoshi, T., ... Koarada, S. (1994). A comparative study of imipenem/cilastatin sodium bid vs qid in the treatment of infections associated with hematopoietic disorders. The Japanese Journal of Antibiotics, 47(10), 1318-1328. https://doi.org/10.11553/antibiotics1968b.47.1318

Sawae, Y, Niho, Y, Okamura, T, Murakawa, M, Teshima, T, Fujisaki, T, Ikeda, K, Kozuru, M, Uike, N, Katsuno, M, Takahira, H, Hashimoto, M, Yamashita, S, Obama, K, Nishimura, J, Hisano, S, Morioka, E, Ishibashi, M, Akiyoshi, T, Suzumiya, J, Nakajima, H, Uchida, T, Yoshida, T, Asahara, F, Sakai, K, Takeichi, N, Ishikura, H, Takita, A, Asayama, R, Shibuya, T, Yamasaki, K, Taniguchi, S, Gondoh, H, Hayashi, S, Akashi, K, Motomura, S, Ishimaru, T, Yamamoto, Y, Ikeda, K, Yamano, Y, Iwasaki, H, Sano, M, Ohta, Y, Matsuishi, E, Hiramatsu, S, Masumoto, A, Kishikawa, H & Koarada, S 1994, 'A comparative study of imipenem/cilastatin sodium bid vs qid in the treatment of infections associated with hematopoietic disorders', The Japanese Journal of Antibiotics, vol. 47, no. 10, pp. 1318-1328. https://doi.org/10.11553/antibiotics1968b.47.1318

@article{b937506c8499413fbd121c4d6c74263d,

title = "A comparative study of imipenem/cilastatin sodium bid vs qid in the treatment of infections associated with hematopoietic disorders",

abstract = "Using the envelope method, we allocated 125 patients with infections accompanied by hematopoietic disorders into two groups treated with imipenem/cilastatin sodium (IPM/CS) at a daily dose of 1 g/1 g b.i.d. (group BID) or 0.5 g/0.5 g q.i.d. (group QID), and obtained the following results. 1. in group BID, ANLL was observed in 25 patients; ALL in 6; and NHL in 12. in group QID, ANLL was observed in 27 patients; ALL in 7; and NHL in 13. 2. in group BID, efficacy rates were 54.5% (6/11) in sepsis, 63.0% (17/27) in fever of undetermined origin and 50.0% (4/8) in pneumonia, thus the overall efficacy was 61.8% (34/55). in group QID, efficacy rates were 66.7% (4/6) in sepsis, 76.0% (19/25) in fever of undetermined origin and 35.7% (5/14) in pneumonia, thus the over all was 61.1% (33/54). No significant difference in response rates were observed between the two groups. 3. Bacteriologically, 22 bacterial strains were isolated in group BID and 21 strains, in group QID. the eradication rates after treatment with IPM/CS was 100% in group BID and 66.7% in group QID. 4. Side effects were observed in 8 patients in group BID and 3 in group QID. Laboratory examination revealed abnormal values in 9 patients in group BID and 6 in group QID. However, all of the side effects desappeared after the suspension or discontinuation of IPM/CS. the efficacies of IPM/CS therapy for severe infections in patients with hematopoietic disease were similar between 1 g/1 g b.i.d. and 0.5 g/0.5 g q.i.d. groups.",

author = "Yoshiro Sawae and Yoshiyuki Niho and Takashi Okamura and Masahiro Murakawa and Takanori Teshima and Tomoaki Fujisaki and Kei Ikeda and Mitsuo Kozuru and Naokuni Uike and Makoto Katsuno and Hiroyuki Takahira and Michi Hashimoto and Sayuri Yamashita and Kousuke Obama and Junji Nishimura and Syusuke Hisano and Eiji Morioka and Morioki Ishibashi and Tomi Akiyoshi and Junji Suzumiya and Hiroaki Nakajima and Toshiki Uchida and Tetsuya Yoshida and Fumitoshi Asahara and Kouko Sakai and Naohisa Takeichi and Hideki Ishikura and Atsushi Takita and Ryokichi Asayama and Tsunefumi Shibuya and Kazuo Yamasaki and Shuichi Taniguchi and Hisashi Gondoh and Shin Hayashi and Kouichi Akashi and Seiji Motomura and Toshiyuki Ishimaru and Yusei Yamamoto and Kimiaki Ikeda and Yujiroh Yamano and Hiromi Iwasaki and Masayuki Sano and Yoshiroh Ohta and Eijo Matsuishi and Shinichi Hiramatsu and Akihiro Masumoto and Hideaki Kishikawa and Shuichi Koarada",

year = "1994",

doi = "10.11553/antibiotics1968b.47.1318",

language = "English",

volume = "47",

pages = "1318--1328",

journal = "The Japanese Journal of Antibiotics",

issn = "0368-2781",

publisher = "Japan Antibiotics Research Association",

number = "10",

}

TY - JOUR

T1 - A comparative study of imipenem/cilastatin sodium bid vs qid in the treatment of infections associated with hematopoietic disorders

AU - Sawae, Yoshiro

AU - Niho, Yoshiyuki

AU - Okamura, Takashi

AU - Murakawa, Masahiro

AU - Teshima, Takanori

AU - Fujisaki, Tomoaki

AU - Ikeda, Kei

AU - Kozuru, Mitsuo

AU - Uike, Naokuni

AU - Katsuno, Makoto

AU - Takahira, Hiroyuki

AU - Hashimoto, Michi

AU - Yamashita, Sayuri

AU - Obama, Kousuke

AU - Nishimura, Junji

AU - Hisano, Syusuke

AU - Morioka, Eiji

AU - Ishibashi, Morioki

AU - Akiyoshi, Tomi

AU - Suzumiya, Junji

AU - Nakajima, Hiroaki

AU - Uchida, Toshiki

AU - Yoshida, Tetsuya

AU - Asahara, Fumitoshi

AU - Sakai, Kouko

AU - Takeichi, Naohisa

AU - Ishikura, Hideki

AU - Takita, Atsushi

AU - Asayama, Ryokichi

AU - Shibuya, Tsunefumi

AU - Yamasaki, Kazuo

AU - Taniguchi, Shuichi

AU - Gondoh, Hisashi

AU - Hayashi, Shin

AU - Akashi, Kouichi

AU - Motomura, Seiji

AU - Ishimaru, Toshiyuki

AU - Yamamoto, Yusei

AU - Ikeda, Kimiaki

AU - Yamano, Yujiroh

AU - Iwasaki, Hiromi

AU - Sano, Masayuki

AU - Ohta, Yoshiroh

AU - Matsuishi, Eijo

AU - Hiramatsu, Shinichi

AU - Masumoto, Akihiro

AU - Kishikawa, Hideaki

AU - Koarada, Shuichi

PY - 1994

Y1 - 1994

N2 - Using the envelope method, we allocated 125 patients with infections accompanied by hematopoietic disorders into two groups treated with imipenem/cilastatin sodium (IPM/CS) at a daily dose of 1 g/1 g b.i.d. (group BID) or 0.5 g/0.5 g q.i.d. (group QID), and obtained the following results. 1. in group BID, ANLL was observed in 25 patients; ALL in 6; and NHL in 12. in group QID, ANLL was observed in 27 patients; ALL in 7; and NHL in 13. 2. in group BID, efficacy rates were 54.5% (6/11) in sepsis, 63.0% (17/27) in fever of undetermined origin and 50.0% (4/8) in pneumonia, thus the overall efficacy was 61.8% (34/55). in group QID, efficacy rates were 66.7% (4/6) in sepsis, 76.0% (19/25) in fever of undetermined origin and 35.7% (5/14) in pneumonia, thus the over all was 61.1% (33/54). No significant difference in response rates were observed between the two groups. 3. Bacteriologically, 22 bacterial strains were isolated in group BID and 21 strains, in group QID. the eradication rates after treatment with IPM/CS was 100% in group BID and 66.7% in group QID. 4. Side effects were observed in 8 patients in group BID and 3 in group QID. Laboratory examination revealed abnormal values in 9 patients in group BID and 6 in group QID. However, all of the side effects desappeared after the suspension or discontinuation of IPM/CS. the efficacies of IPM/CS therapy for severe infections in patients with hematopoietic disease were similar between 1 g/1 g b.i.d. and 0.5 g/0.5 g q.i.d. groups.

AB - Using the envelope method, we allocated 125 patients with infections accompanied by hematopoietic disorders into two groups treated with imipenem/cilastatin sodium (IPM/CS) at a daily dose of 1 g/1 g b.i.d. (group BID) or 0.5 g/0.5 g q.i.d. (group QID), and obtained the following results. 1. in group BID, ANLL was observed in 25 patients; ALL in 6; and NHL in 12. in group QID, ANLL was observed in 27 patients; ALL in 7; and NHL in 13. 2. in group BID, efficacy rates were 54.5% (6/11) in sepsis, 63.0% (17/27) in fever of undetermined origin and 50.0% (4/8) in pneumonia, thus the overall efficacy was 61.8% (34/55). in group QID, efficacy rates were 66.7% (4/6) in sepsis, 76.0% (19/25) in fever of undetermined origin and 35.7% (5/14) in pneumonia, thus the over all was 61.1% (33/54). No significant difference in response rates were observed between the two groups. 3. Bacteriologically, 22 bacterial strains were isolated in group BID and 21 strains, in group QID. the eradication rates after treatment with IPM/CS was 100% in group BID and 66.7% in group QID. 4. Side effects were observed in 8 patients in group BID and 3 in group QID. Laboratory examination revealed abnormal values in 9 patients in group BID and 6 in group QID. However, all of the side effects desappeared after the suspension or discontinuation of IPM/CS. the efficacies of IPM/CS therapy for severe infections in patients with hematopoietic disease were similar between 1 g/1 g b.i.d. and 0.5 g/0.5 g q.i.d. groups.

UR - http://www.scopus.com/inward/record.url?scp=0028034384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028034384&partnerID=8YFLogxK

U2 - 10.11553/antibiotics1968b.47.1318

DO - 10.11553/antibiotics1968b.47.1318

M3 - Article

C2 - 7807693

AN - SCOPUS:0028034384

SN - 0368-2781

VL - 47

SP - 1318

EP - 1328

JO - The Japanese Journal of Antibiotics

JF - The Japanese Journal of Antibiotics

IS - 10

ER -

A comparative study of imipenem/cilastatin sodium bid vs qid in the treatment of infections associated with hematopoietic disorders

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this